We are pleased to share the recently published updated guidance on Crohn’s and Ulcerative Colitis for adults over sixteen from the British Society of Gastroenterology. It includes the first ever mention of RHB-104, the combined antibiotic pill which has been successfully trialled by Redhill Biopharma; this large RCT addresses the mycobacteria which we believe is at the root of the Crohn’s disease and which the Crohn’s MAP Vaccine is also designed to target. We are delighted to see antibiotic treatment included in the new guidance and hope that the BSG will be following the progress of the vaccine trials with interest!